Needham raised the firm’s price target on Glaukos (GKOS) to $176 from $149 and keeps a Buy rating on the shares after its Q4 results. The ...

Glaukos reported Q4 sales of $105.5 million, surpassing estimates, while EPS missed. Analysts see strong growth potential as ...

Glaukos' fourth-quarter results showcase a strong uptick in revenues. However, continued operating loss and rising OpEx ...

Wells Fargo raised the firm’s price target on Glaukos (GKOS) to $160 from $153 and keeps an Overweight rating on the shares. The firm notes ...

Principal Financial Group Inc. lessened its stake in shares of Glaukos Co. (NYSE:GKOS – Free Report) by 6.9% in the 4th quarter, according to its most recent 13F filing with the Securities and ...

Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial results and a robust product ...

Fintel reports that on February 19, 2025, Mizuho upgraded their outlook for Glaukos (NYSE:GKOS) from Neutral to Outperform.

Rhumbline Advisers lifted its holdings in Glaukos Co. (NYSE:GKOS – Free Report) by 0.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The ...

Glaukos Corp (GKOS) reports robust sales growth and outlines strategic initiatives for 2025, while navigating currency and reimbursement challenges.

Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ETCompany ParticipantsChris Lewis - Vice President, ...

ALISO VIEJO, Calif. (AP) — ALISO VIEJO, Calif. (AP) — Glaukos Corp. (GKOS) on Thursday reported a loss of $33.6 million in its fourth quarter. On a per-share basis, the Aliso Viejo, California-based ...